LDHA and neoplasm: The administration of the LDHA inhibitor FX-11 leads to a notable augmentation of tumour-infiltrating CD8 + T and NK cells in the mice model, thereby potentially enhancing the responsiveness of tumours to anti-PD-1 immunotherapy in the MPS2 subtype [84].